{
  "module": "askmo_plugin_itepekimab_logic",
  "blueprint_id": "ITEPEKIMAB-χ1",
  "enabled": true,
  "aliases": [
    "itepekimab rescue",
    "IL-33 SEI logic",
    "Regeneron COPD failed drug",
    "χ1 COPD modulator",
    "MDC-FDC hybrid IL33",
    "chi1 repair lung drug"
  ],
  "response_priority": [
    "mechanism_map_IL33_logic.svg",
    "entropy_profile_itepekimab_chi1.json",
    "responder_subgroup_sim.json",
    "repair_circuit_overlay.json",
    "failure_forensics_report.pdf",
    "drug_logic_scorecard.md"
  ],
  "fallback_summary": "ITEPEKIMAB-χ1 is a SEI-rescued blueprint derived from the failed Regeneron IL-33 antibody trial in COPD. It corrects key faults using logic-based modulation, epithelial repair, and cytokine compensation suppression.",
  "core_logic_nodes": [
    "Partial IL-33 modulation via MDC",
    "IL-1β and IL-17A suppression via FDC gatekeepers",
    "Epithelial restoration circuit using zinc and selenium logic",
    "Trial stratification based on IL-33 and EDI biomarkers",
    "Entropy stabilization across 52 weeks"
  ],
  "entropic_signature": {
    "stability_class": "Class I",
    "sei_score": 91.2,
    "confidence": 0.94
  },
  "qa_examples": [
    {
      "question": "Why did the original Itepekimab trial fail?",
      "answer_source": "failure_forensics_report.pdf"
    },
    {
      "question": "How is χ1 different from Itepekimab?",
      "answer_source": "original_vs_chi1_blueprint_diff.json"
    },
    {
      "question": "What are the trial design changes in χ1?",
      "answer_source": "copd_repair_trial_design.json"
    },
    {
      "question": "Does χ1 stimulate lung repair?",
      "answer_source": "repair_circuit_overlay.json"
    },
    {
      "question": "What kind of patient will respond to χ1?",
      "answer_source": "responder_subgroup_sim.json"
    }
  ],
  "sei_charter_compliant": true,
  "activation_scope": "Tier 3+ Ask Moleculogic runtime"
}
